Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia
NCT07484204
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
AX251 LAI 45 mg
DRUG:
AX251 LAI 90 mg
DRUG:
AX251 LAI 135 mg
DRUG:
AX251 LAI 180 mg
Sponsor
Anxo Pharmaceutical Co., Ltd.